CHICAGO, July 23, 2024 /PRNewswire/ -- The global Molecular Diagnostics Market is expected to grow from USD 17.3 billion in 2024 to USD 32.7 billion by 2029, at a CAGR of 13.5%. This growth is driven by increased government funding for precision medicine and genomics, amplifying the usage of molecular diagnostics kits and instruments. Additionally, the rising number of hospitals in developed and emerging economies, driven by high patient influx, is boosting the demand for precise molecular-based testing. Technological advancements in portability and quick turnaround times have made it easier for smaller facilities to integrate molecular testing into their workflows. Increased investment and emphasis on R&D, supported by government initiatives and funding, further enable growth prospects in the molecular diagnostics market. However, the high cost of molecular diagnostic products may limit growth, as only large hospitals and reference laboratories with substantial capital budgets can afford them. Opportunities for growth are present in developing economies such as South Africa, Brazil, Turkey, Russia, and India, where high disease prevalence, a sizable patient base, better healthcare facilities, rising disposable incomes, and increased medical tourism contribute to market expansion. The evolving regulatory environment for IVD and molecular diagnostics in the US and European nations poses challenges to market growth. In 2023, the reagents & kits segment held the largest share of the market by product & service, while the lab tests segment led by test type. The PCR segment dominated the market by technology. North America accounted for the largest share of the molecular diagnostics market in 2023, driven by advanced healthcare systems and increased adoption of cutting-edge technologies. Key players in the market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US), known for their extensive product portfolios and wide geographic presence.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833
Browse in-depth TOC on "Molecular Diagnostics Market"
546 - Tables
55 - Figures
453 - Pages
DANAHER (US): Leader in Molecular Diagnostics
In 2023, Danaher emerged as the top player in the molecular diagnostics market. The company's established presence within the US provides a strong foundation for expansion into emerging economies, fostering a broader global footprint. Danaher also demonstrates a commitment to continuous product development, catering to the diverse needs of its international customer base, which further strengthens the company's market leadership. Moreover, the company maintains its competitive edge through robust research and development initiatives, coupled with efficient supply chain management. Organic growth strategies, such as product launches and regulatory approvals, also play a significant role. For example, in March 2024, the company received clearance from the US FDA for the Xpert Xpress GBS test. Similarly, in November 2022, the company launched the Xpert Xpress MVP, a multiplexed PCR test. These strategic actions contribute to Danaher's sustained dominance within the molecular diagnostics market.
F. HOFFMANN-LA ROCHE LTD (Switzerland): Market Leader in Molecular Diagnostics
In 2023, F. Hoffmann-La Roche Ltd. commanded a substantial market share within the molecular diagnostics market. This leadership position stems from their extensive distribution network spanning North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. This comprehensive reach mitigates regional demand fluctuations and ensures consistent product availability globally. Furthermore, Roche employs strategic acquisitions to solidify its market dominance. For instance, in March 2021, the company entered into a merger with GenMark Diagnostics (US) to access novel technologies for testing a broad range of pathogens in one patient sample. These strategic moves strengthen Roche's product offerings and technological capabilities, securing their position as a key player in the molecular diagnostics market.
ILLUMINA, INC. (US): Key Player in Molecular Diagnostics
In 2023, Illumina, Inc. held a prominent position in the molecular diagnostics market. Building on a strong foundation in the US, the company actively pursues geographic expansion through strategic investments in emerging markets. This commitment to international growth strengthens Illumina's market position. Furthermore, a robust product portfolio, encompassing FDA and CE-approved solutions, has significantly contributed to the company's substantial market share.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=833
Product Segmentation: Reagents & Kits Lead the Molecular Diagnostics Market
The global molecular diagnostics market is segmented by product & service into reagents & kits, instruments, and services & software. In 2023, the reagents & kits segment accounted for the largest share of the molecular diagnostics market. The large share and high growth rate of this segment can be attributed primarily to the need for large quantities of these consumables compared to instruments. As molecular diagnostics become increasingly integrated into routine testing protocols for a wider range of diseases, diagnostic laboratories and healthcare facilities experience a constant rise in daily test volume, necessitating a consistent supply of reagents and kits. This translates into frequent repeat purchases by end-users, thus solidifying the reagents & kits segment as a reliable and predictable revenue stream within the molecular diagnostics market.
Technology Segmentation: PCR Dominates
The molecular diagnostics market is categorized by technology into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies. In 2023, the largest share of the molecular diagnostics market was held by the polymerase chain reaction (PCR) segment. The market dominance of PCR is driven by several key factors such as PCR's established role in proteomics and genomics research, and the automation of PCR instruments to streamline workflows and significantly increase testing throughput. Moreover, optimized protocols, readily available commercial kits, and reliable reagents streamline the implementation of PCR for laboratories. Furthermore, the growing focus on personalized medicine fuels demand for PCR assays tailored to individual patients, propelling continued growth within the PCR segment.
Regional Insights: Asia Pacific Offers Significant Growth Opportunities
The global molecular diagnostics market has been segmented into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the molecular diagnostics market during the forecast period. Increased government initiatives to support early disease detection, rising per capita incomes, and the existence of dynamic, high-growth markets within the region are some of the factors driving growth in this market. Additionally, more favorable regulatory frameworks and reduced labor expenses are expected to support market expansion in the Asia Pacific region.
For more information, inquire now! Inquire Now
Related Reports:
In Vitro Diagnostics Market
Point of Care Molecular Diagnostics Market
Companion Diagnostics Market
Infectious Disease Diagnostics Market
Cancer Diagnostics Market
Get access to the latest updates on Molecular Diagnostics Companies and Molecular Diagnostics Market Share
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/molecular-diagnostics-market-worth-32-7-billion-by-2029-driven-by-increasing-technological-advancements--marketsandmarkets-302203749.html
